Acute respiratory illnesses (ARIs) caused by respiratory viruses including influenza viruses and respiratory syncytial virus (RSV) affect hundreds of millions of people per year and are the most common causes of viral infections in the respiratory tract in humans ([@bb0005], [@bb0015], [@bb0045]). Each year, approximately 500 million cases of ARI are reported in the United States, with direct and indirect costs approaching \$40 billion annually ([@bb0005], [@bb0015]).

The 2009 H1N1 pandemic strain of influenza and the H3N2 seasonal variant that circulated during the 2014--2015 season serve as examples of the importance of continued respiratory virus surveillance efforts, and the importance of using accurate and inclusive diagnostics in respiratory virus management ([@bb0020], [@bb0025], [@bb0030]). In addition, given the emergence of Middle East respiratory syndrome (MERS) coronavirus and subsequent outbreaks thereof in the Middle East and South Korea, it is important that diagnostic assays for respiratory viruses are rapid and deployable at or near the point of care (POC) ([@bb0010], [@bb0035]). Such diagnostic platforms are becoming more common and are capable of detecting a wide array of respiratory pathogens ([@bb0050]).

We evaluated a novel, portable, near-POC diagnostic platform, the Mobile Analysis Platform (MAP), by assessing the capability of the MAP to detect influenza A, influenza B, and RSV in externally extracted clinical samples, and by establishing the platform\'s limit of detection (LOD) for RSV and MERS in clinical matrices.

The MAP is a small, portable device integrating disposable assay-specific microfluidic cards ([Fig. 1](#f0005){ref-type="fig"} ). The MAP system is equipped with a set of subsystem to allow for automatic assay processing. This includes A) a barcode reader to input both specimen and microfluidic card serial numbers; B) a motorized system to crush liquid reagent packs on command; C) a pneumatic system (air pressure and vacuum) to move liquids within the cards via peristaltic pumping using vacuum-actuated midstream valves (specimens are thus mixed with various reagents prepackaged into the cards in lyophilized beads to move sample and reagents on the microfluidics card); and D) a set of thermal electric coolers to allow for rapid polymerase chain reaction (PCR; 30 min for 40 cycles) PCR cycling of the mixed sample and reagents is performed in a chamber sandwiched between 2 thermoelectric cooling devices; E) heating elements to maintain temperature at a separate hybridization chamber; F) an optics system that includes a LED for dye excitation and CCD camera for imaging the microarray; G) an ARM processor; H) an LCD screen; and I) keypad.Fig. 1Respiratory array card design for the MAP unit. 1) Black squares indicate the position of fiducial spots used to home the camera prior to reading the array card. 2) Light purple squares indicate the position of hybridization control spots. 3) Dark green squares indicate MERS target hybridization spots. 4) Dark yellow squares indicate the position of influenza A virus target hybridization spots. 5) Light blue squares indicate the position of influenza B virus target hybridization spots. 6) Dark purple squares indicate the position of RSV target hybridization spots. 7) Red squares indicate the position of array spots that are open and could accommodate other respiratory virus targets. 8) Light yellow squares indicate internal control target hybridization spots. 9) Light green squares indicate human DNA target hybridization spots.Fig. 1

The microfluidics card is disposable and has all the materials required for the assay including A) sample port to load the swab, B) wet reagents held in sealed blister packs, C) lyophilized reagents, and D) a microarray chip. The microarray chip consists of 100-μm spots of specific DNA capture probes. The array has 400 of these features, with 100 features reserved for image alignment. This allows up to 300 separate spots for the assay. PCR products are then digested using uracil deglycosylase and hybridized to a spotted microarray and washed. The microarray is then imaged with a digital camera and LED illumination, and the image is analyzed and statistically interpreted via onboard analysis software. The entire process is fully automated, and results are presented as positive/negative/invalid declarations on the screen of the MAP unit. Multiple primer pair/probe combinations are employed for each analyte, each of which is designed to offer maximum breadth of coverage within the known diversity of the targeted viral genus.

A total of 130 clinical respiratory virus samples were evaluated, including both nasopharyngeal swab samples resuspended in VTM (*N* = 85) and nasal wash samples (*N* = 45) composed of true positives for influenza A (*N* = 93), influenza B (*N* = 21), and RSV (*N* = 7), and samples that were negative for these analytes (*N* = 9). Samples were acquired through institutional review board-approved studies (IRB00052743, NHRC.2015.0033) from adults ≥18 years old that were symptomatic for a respiratory virus infection. Influenza A and B samples previously tested positive via the Cepheid Xpert Flu assay (Cepheid, Sunnyvale, CA) or CDC Human Influenza Virus Real-Time PCR Diagnostic Panel (US Centers for Disease Control and Prevention, Atlanta, GA), while RSV samples previously tested positive via a published real-time PCR assay ([@bb0040]). LOD experiments were performed for RSV and MERS by spiking virus into negative clinical matrix. When available, leftover extracts from initial clinical diagnostic testing were utilized. When these were not available, the same methods were used to generate new extracts from waste aliquots of the specimens. Nucleic acids were extracted using either the Arrow Viral NA Kit (NorDiag) or the DSP Viral Mini Kit (Qiagen). Extracted nucleic acid was loaded onto individual MAP assay cards, which were then run and analyzed on portable MAP devices according to the manufacturer\'s instructions. Primer sequences for the target organisms can be found in [Table 1](#t0005){ref-type="table"} , with reagent concentrations for the array cards listed in [Table 2](#t0010){ref-type="table"} .Table 1Primer sequences and targets for MAP respiratory virus array.Table 1OrganismMolecular targetProduct size (bp[a](#tf0005){ref-type="table-fn"})Primer nameSequenceInfluenza AM1110VIR13095FTCAGGCUCCCUCAAAGCCGAVIR13096R/5MAXN[b](#tf0010){ref-type="table-fn"}/TGCAGGATTGGTCTTGTCTTTAICCAInfluenza APA74VIR13099FCTUGAGAAUTTUAGAGCCUATGUIGAUGGVIR13100R/5MAXN/CACATTTGAGAAAGCTTGCCCTCAATInfluenza BPB183VIR13470FCAGGCAGCAAUTUCAACAACATUCCCVIR13471R/5MAXN/TTGTCTATTGTGTAGCCTGTTCCTGTTCInfluenza BPA78VIR13491FGGAGGGAAAAAUCUGTGUACCTGUATUGCVIR13492R/5MAXN/TAGCTTCCATTCCCCATTTCATTTGGATRSVMatrix protein83VIR13361FAAGAUGGGGCAAAUAUGGAAACAUACGUGAAVIR13363R/5MAXN/TAGAACATTGTACTGAACAGCTGCTGTGTAVIR13362R/5MAXN/TAGGACATTGTATTGAACAGCAGCTGTGTARSVPhosphoprotein84VIR13355FTCGGCUCGUGAUGGAAUAAGAGAUGCVIR13357FTCUGCUCGGGAUGGUATAAGAGAUGCVIR13356R/5MAXN/CGTCATTAATGCTTCAGTTCTGATTTTTTCTATCATVIR13358R/5MAXN/CGTCATTAATGCTTCTGCTCTTATTTTTTCTATCATMERSOrf1A protein92VIR13088FCGGCCUUCAACUGGUUGUUGUUVIR13089R/5MAXN/AGCATAATTGTATGACCGCCAGTCMERSN protein102VIR13090FCCUGUGUACUUCCUUCGGUACAGUVIR13091R/5MAXN/GTAGGCATCAATATTTTGCTCAAGAAGC[^1][^2][^3]Table 2Reagent concentrations for the MAP respiratory virus assay cards.Table 2*UDG (Excipient X4)---100 μL in digestion well*10 U UDG3% Trehalose1.5 mmol/L Tris7.5 mmol/L KCL0.015 mmol/L EDTA0.15 mmol/L DTT0.0015 % BSA50.00 nM hybridization control  *Kapa (Excipient X2.2)---150 μL in PCR Master Mix chamber*16 U Kapa2 % Trehalose266.67 μmol/L dNTP mixture4.67 mmol/L MgCL~2~1.33 X Buffer A  *SSIII (Excipient A)---150 μL in MM chamber*^*c*^50 U SuperScript III2 % Trehalose5 mmol/L Tris1 mmol/L ammonium sulfate1.2 mmol/L MgCL~2~0.005 % Tween-400.4 mmol/L DTT0.015 μg random primers0.03 μg Poly-A[^4]

Cycling conditions were as follows: RT step, 5 min at 52 °C; Hotstart step, 30 s at 95 °C; and extended touchdown PCR and fast PCR, 1 cycle of 7 s at 95 °C, 1 s at 55 °C, 30 s at 69.5 °C, 2 s at 80 °C followed by 1 cycle of 7 s at 95 °C, 1 s at 53.5 °C, 30 s at 67 °C, 2 s at 80 °C followed by 1 cycle of 7 s at 95 °C, 1 s at 51 °C, 30 s at 65 °C, 2 s at 80 °C followed by 1 cycle of 7 s at 95 °C, 1 s at 50 °C, 30 s at 63 °C, 2 s at 80 °C followed by 1 cycle of 7 s at 95 °C, 1 s at 49 °C, 30 s at 62 °C, 2 s at 80 °C followed by 35 cycles of 7 s at 95 °C, 1 s at 45 °C, 5 s at 65 °C and 2 s at 80 °C. All ramp rates on approach to 80 °C were dampened to 20% of maximum. Time to result including nucleic acid extraction was 110 min per sample. All results are reported here as they appeared on the automated output of the MAP devices. Samples that generated either an invalid result or an error report were recorded as assay failures and were not repeated.

Percent agreement between MAP and standard-of-care reverse transcriptase PCR results was 97% (73/75) for influenza A-positive samples, with 2 false-negative results and 18 assay failures resulting in invalid or error reports. Percent agreement for influenza B was 100% (21/21) with no assay failures and 100% (6/6) for RSV with 1 assay failure. Agreement was 80% (4/5) for negative samples, with 1 RSV-positive result and 4 assay failures. The LOD established was 30 and 1500 copies of virus/assay for RSV and MERS coronavirus, respectively.

Previous epidemics and pandemics, as well as the emergence of new respiratory viral pathogens, highlight the need for accurate diagnostic platforms capable of being deployed near the POC ([@bb0050]). We performed an evaluation of the MAP prototype to determine its capability to detect and identify influenza A, influenza B, and RSV, and performed LOD experiments in clinical matrix for RSV and MERS. Percent agreement between the MAP assay result and the predicate result were high for all pathogens evaluated (97--100%) when excluding invalid assay card results and error reports (no-test instances), and LOD experiments for RSV and MERS yielded acceptable LODs.

An ideal evaluation would have included enough positive and negative samples to calculate sensitivity and specificity at the lower bound of the 95% confidence interval, as opposed to calculating percent agreement. However, based on the limited number of array cards available for this evaluation, it was more important to evaluate as many positive samples as possible to gauge the capability of the array cards to amplify pathogens.

For MERS, an ideal evaluation would have included clinical samples; however, given the rarity and difficulty in acquiring MERS positive clinical samples, this was not possible for this evaluation.

In instances where an invalid result was generated, it was almost exclusively the result of variable fluid handling in the array card, which could be overcome by modifying the technology utilized for fluid handling on the MAP unit. Additional improvements to the MAP unit would also include combining the extraction and amplification process into one instrument, which would bring the MAP unit closer to being a POC diagnostic and meeting ASSURED criteria.

Clearly, there are limitations to the study; most notably, sensitivity and specificity for the assay were not calculated due to the low number of negative samples evaluated. Future studies would ideally include a large increase in the number of negative samples evaluated, as well as performing the study in a prospective manner.

While this technology is in early stages of development and, as such, yielded a high rate of invalid (no test) results, percent agreement with clinical laboratory methods approached 97% for completed tests. This technology shows promise as a rapid, accurate, deployable diagnostic technology for automated detection and discrimination of multiple pathogens in clinical sample extracts.
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[^1]: Organism targets, predicted PCR product size, primer name, and primer sequences are listed here.

[^2]: Base pairs.

[^3]: 5MAX (NHS ester).

[^4]: Composition of each of the 3 lyophilized bead reagents provided with the Map cards, and the resulting reagent concentrations or compositions following resuspension thereof in the chambers of the card in which the beads were packages are represented. Super Script III (Life Technologies, Carlsbad, CA).
